Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-beta peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC 50: 220 nM), CDK5/p25 (IC 50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1delta provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-beta in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DRF05322, a CR8-related inhibitor that carries a differently linked phenylpyridine ring system (Fig. 3a, c), induced binding with two-fold lower affinity than CR8 (Extended Data Fig. 8a).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [22]
Citations
Cites
Boys, S. F., & Bernardi, F. (1970) · Molecular Physics · doi:10.1080/00268977000101561 · Cited by 22,188
Mohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Lipton, M., Caufield, C., Chang, G., Hendrickson, T., & Still, W. C. (1990) · Journal of Computational Chemistry · doi:10.1002/jcc.540110405 · Cited by 3,757
ESPript: analysis of multiple sequence alignments in PostScript.
Gouet, P., Courcelle, E., Stuart, D. I., & M√©toz, F. (1999) · Bioinformatics · doi:10.1093/bioinformatics/15.4.305 · Cited by 2,951
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Self-citationGSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Self-citation
Research works printed but not linked: 6
- Manning G., 2002, Science, 298, 1933
- Meijer L., 2003, Acc. Chem. Res., 36, 417, 10.1021/ar0201198 · doi:10.1021/ar0201198
- Meijer L., 2006, CDK Inhibitors and their Potential as Antitumor Agents, 2, 187
- Menn B., 2008, Ann. Neurol.
- Rockenstein E., 2007, J. Neurosci., 27, 1981, 10.1523/JNEUROSCI.4321-06.2007 · DOI · Paper page
- Bettayeb K., 2008, Oncogene
Cited by
Items 101–164 of 164
Zhang, B., Su, Z., Tay, T. E., & Tan, V. B. C. (2009) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0629-4 · Cited by 10
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present
Huang, X., Xu, S., Duan, L., Xu, S., & Zhu, W. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379926 · Cited by 10
“● Although some CDK4/6 inhibitors have been approved for the treatment of breast cancer, addressing the existing challenges of drug resistance and high toxicity will be a trend in CDK4/6 inhibitor research. micromolar concentrations micromolar concentrations [29].”
Myrianthopoulos, V., Lozach, O., Zareifi, D., Alexopoulos, L. G., Meijer, L., Gorgoulis, V. G., & Mikros, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102102 · Cited by 9
Self-citationPharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice
Sallam, H., Serafi, I. E., Meijer, L., & Hassan, M. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-50 · Cited by 7
Self-citationChen, N., Yang, H., Niu, J., & Liu, S. (2013) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6537 · Cited by 7
Erdő, F., Nagy, I., Tóth, B., Bui, A., Molnar, E. M., Tímár, Z., Magnan, R., & Krajcsi, P. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.06.013 · Cited by 8
Wang, Z., Zhang, K., Huang, M., Shang, D., He, X., Wu, Z., Xu, Y., & Zhang, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.019 · Cited by 7
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Troadec, S., Blairvacq, M., Oumata, N., Galons, H., Meijer, L., & Berthou, C. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0163-x · Cited by 6
Self-citationA Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors
Krajčovičová, S., Gucký, T., Hendrychová, D., Kryštof, V., & Soural, M. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b02650 · Cited by 6
Grieco, I., Bassani, D., Trevisan, L., Salmaso, V., Cescon, E., Prencipe, F., Ros, T. D., Martínez‐González, L., Martínez, A., Spalluto, G., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107659 · Cited by 5
Medda, F., Smith, B. E., Gokhale, V. M., Shaw, A. Y., Dunckley, T. L., & Hulme, C. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00005-3 · Cited by 6
Tsui, H., Zeng, Q., Chen, K., & Zhang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13815-6 · Cited by 6
Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents
Yadav, M. R., Barmade, M. A., Chikhale, R. V., & Murumkar, P. R. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_14 · Cited by 7
Central Modulation of Circadian Rhythm via CK1 Inhibition for Psychiatric Indications
Galatsis, P., Wager, T. T., Offord, J., DeMarco, G. J., Ohren, J. F., Efremov, I. V., & Mente, S. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00024-2 · Cited by 4
Wang, W., Cao, X., Zhu, X., & Gu, Y. (2013) · Journal of Molecular Modeling · doi:10.1007/s00894-013-1815-y · Cited by 4
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Protein and Peptide Letters · doi:10.2174/0109298665348075241121071614 · Cited by 3
Culletta, G., Almerico, A. M., & Tutone, M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673331207241019085108 · Cited by 3
Ham, Y. J., Lee, D., Choi, H. G., Hah, J.-M., & Sim, T. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.06.056 · Cited by 3
Dong, K., Wang, X., Yang, X., & Zhu, X. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.06.007 · Cited by 4
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme
Spinaci, A., Lambertucci, C., Chang, C., Buccioni, M., Marucci, G., Cescon, E., Federico, S., Spalluto, G., Ben, D. D., & Volpini, R. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03202-6 · Cited by 2
“Adenine represents an important starting point for the development of CK1 δ inhibitors, such as the roscovitine derivative ( R )-DRF053 (IC 50 value of 14 nM) and the compounds SR-653234 (IC 50 of 160 nM) and SR-2890 (IC 50 of 4 nM) [21, 22].”
Wang, J., Hu, Y., Zhou, K., Wang, W., Li, F., Li, K., Zhang, G., & Tang, Y. (2023) · Molecules · doi:10.3390/molecules28093975 · Cited by 2
Mabondzo, A. M., Disdier, C., Bouzid, A., Larbi, K. S., Tsintzou, A., Maïza, A., Kim, B., Costa, N., Harati, R., Nguyen, A. L., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00621 · Cited by 2
“Several trisubstituted purines and some structurally related heterocycles are kinase inhibitors [45,46].”
Self-citationYang, Y., Zhou, B. N., Jiang, J., Yang, J., & Li, S. (2022) · Heterocycles · doi:10.3987/com-22-14722 · Cited by 2
Therapeutic targeting of CDK12: a medicinal chemistry perspective
Wang, F., Dai, H., Wan, K., & Wang, M. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118552 · Cited by 1
Roscovitine derivative optimization via molecular dynamics reveals potent and selective CDK5 binders
Botta, L., Carotenuto, G., Arcieri, M., Nisio, E. D., Perticaroli, V., Castrignanò, T., Saladino, R., & Negri, R. (2026) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2026.1741100 · Cited by 1
Décout, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14915-7 · Cited by 1
Zhai, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00004-8 · Cited by 1
2,6-Dichloro-7-isopropyl-7H-purine
Hloušková, N., Rouchal, M., Nečas, M., & Robert Vícha, A. (2012) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s160053681201879x · Cited by 1
“For the synthesis, see: Oumata et al. (2008).”
MethodPharmacological and analytical studies of the cyclin dependent kinase inhibitors
Sallam, H. (2009) · Figshare · Cited by 2
Rajnai, Z. (2018) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.4218 · Cited by 1
Dawson, M. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738066001.793575550
Ross, I. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-04239-2_6
Banet, M., Crespi, V., Elie, J., Riahi, Y., Lakli, M., Mareux, E., Gonzales, E. M., Jacquemin, E., Meijer, L., Lapalus, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-39840-6
“3 and was performed as published 46–50 and patented (World Intellectual Property Organization, WO2022061155; European Patent Organization, EP4268824).”
Self-citationN'gompaza‐Diarra, J. (2012) · theses.fr (ABES) · doi:10.70675/6f03bc10zd5a4z414eza3c0z67e0b10f79f6
Méthodologie en chimie hétérocyclique et application à la synthèse d'inhibiteurs de kinases
Pellegatti, L. (2010) · theses.fr (ABES) · doi:10.70675/1f179f32z6894z44e9zb46fzfb9aed18c3f3 · Cited by 1
A patent review of cyclin-dependent kinase 5 (CDK5) inhibitors (1999–2025)
Derzhavina, V. M., Khalymbadzha, I. А., & Yuzhalin, A. E. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1843047
BindingDB Entry 50019728: Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q2fx7fv6
BindingDB (2020) · UC San Diego · doi:10.7270/q2m61npg
BindingDB Entry 50007386: Small molecule modulators targeting protein kinase CK1 and CK2.
BindingDB (2021) · UC San Diego · doi:10.7270/q29k4fjb
BindingDB Entry 50042731: Synthesis and biological evaluation of guanidino analogues of roscovitine.
BindingDB (2013) · UC San Diego · doi:10.7270/q24x5951
BindingDB Entry 50031457: Selectively nonselective kinase inhibition: striking the right balance.
BindingDB (2010) · UC San Diego · doi:10.7270/q2vd6zk0
Metadata
- Authors
- Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., Meijer, L., & Galons, H.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Laboratoire de Chimie Organique 2, INSERM U 648, Université Paris-Descartes, 4 avenue de l’Observatoire, 75270 Paris cedex 06, France, CNRS, Protein Phosphorylation & Human Disease Group, Station Biologique, B.P. 74, 29682 Roscoff cedex, Bretagne, France, Department of Pharmacy, University of Athens, GR-15771 Athens, Greece, Laboratory of Molecular & Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, New York 10065-6399
- Corresponding author
- Meijer, Laurent
- Galons, Hervé
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-08-13
- Volume
- 51
- Issue
- 17
- Pages
- 5229-5242
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1989404928
- Semantic Scholar
- 7e66b22e8142658b493b4a260facbc3977df92ba
- Cited by
- 139
- References
- 54
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 10 · 2016: 7 · 2015: 5 · 2014: 5 · 2013: 12 · 2012: 12
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- National Institute on Aging (AG09464, P01AG009464)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- cyclin-dependent kinases, casein kinase 1, Alzheimer's disease, amyloid-beta production, tau hyperphosphorylation, CDK1/cyclin B, CDK5/p25, antiproliferative activity, kinase inhibitors
- MeSH terms
- Roscovitine, Animals, Binding Sites, Cell Line, Humans, Models, Molecular, Purines, Structure-Activity Relationship, Amyloid beta-Peptides, Cyclin-Dependent Kinases, Inhibitory Concentration 50, Casein Kinase I, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.